By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kite Pharma, Inc. 

2225 Colorado Avenue

Santa Monica  California  90404  U.S.A.
Phone: 301-824-9999 Fax: n/a


Company News
JPM17: Kite Pharma (KITE)'s Strategy for Commercializing Its Lead CAR-T Drug 1/12/2017 6:44:40 AM
On a Roll: Kite Pharma (KITE) Bags $250 Million CAR-T Deal From Daiichi Sankyo, Forms Joint Venture With Fosun Pharma 1/9/2017 2:30:05 PM
Kite Pharma (KITE) Enhances Commercial Expertise With The Appointment Of Ian T. Clark To Its Board Of Directors 1/5/2017 11:23:58 AM
Kite Pharma (KITE) Submits Investigational New Drug (IND) Application For KITE-718, An Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 And MAGE A6 1/3/2017 8:28:55 AM
Juno (JUNO) Defeats Kite Pharma (KITE)’s Challenge To CAR T-Cell Patent 12/19/2016 9:28:48 AM
Kite Pharma (KITE) Announces Successful Defense Of Roberts Patent And Intent To Appeal U.S. Patent And Trademark Office Decision On A Narrow Patent Focused On Select CD28 CAR-T Products 12/19/2016 9:22:00 AM
Kite Pharma (KITE) And Vitruvian Networks Enter Strategic Partnership To Develop Best-In-Class Logistics And Data Analytics Software For Engineered T-Cell Therapies At Commercial Scale 12/13/2016 8:16:17 AM
Kite Pharma (KITE) Announces Publication Of T-Cell Therapy Targeting Mutant KRAS In Cancer By The NCI In The New England Journal of Medicine 12/12/2016 10:33:13 AM
Kite Pharma (KITE) Presents Results Of Multi-Center Pivotal ZUMA-1 Trial Of Axicabtagene Ciloleucel (KTE-C19) In Aggressive Non-Hodgkin Lymphoma As Late-Breaking Abstract At Annual Meeting Of American Society of Hematology 12/6/2016 10:45:33 AM
Kite Pharma (KITE) Initiates Rolling Submission Of U.S. Biologics License Application (BLA) For KTE-C19, Its Investigational Anti-CD19 CAR-T Therapy, For The Treatment Of Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL) 12/5/2016 1:07:32 PM